References
- World Federation of Neurology Research Group on Neuro- muscular Diseases Subcommittee on Motor Neuron Disease. Airlie House guidelines. Therapeutic trials in amyotrophic lateral sclerosis. Airlie House ‘ Therapeutic Trials in ALS’ Workshop Contributors. J Neurol Sci 1995; 129(Suppl): 1–10.
- Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci 1999; 169: 2–12.
- Miller RG, Rosenberg JA, Gelinas DF et al and the ALS Prac- tice Parameters Task Force. Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence- based review). Report of the Quality Standards Subcommit- tee of the AAN. Neurology 1999; 52: 1311–1323.
- National Institute for Clinical Excellence (NICE). Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease. Technology Appraisal Guidance. No. 20, London: NICE, 2001.